Cell Biotech Statistics
Total Valuation
Cell Biotech has a market cap or net worth of KRW 93.08 billion. The enterprise value is 4.70 billion.
| Market Cap | 93.08B |
| Enterprise Value | 4.70B |
Important Dates
The last earnings date was Friday, February 13, 2026.
| Earnings Date | Feb 13, 2026 |
| Ex-Dividend Date | Dec 29, 2025 |
Share Statistics
Cell Biotech has 6.84 million shares outstanding.
| Current Share Class | 6.84M |
| Shares Outstanding | 6.84M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 35.37% |
| Owned by Institutions (%) | 8.75% |
| Float | 4.42M |
Valuation Ratios
The trailing PE ratio is 7.39.
| PE Ratio | 7.39 |
| Forward PE | n/a |
| PS Ratio | 1.84 |
| PB Ratio | 0.73 |
| P/TBV Ratio | 0.74 |
| P/FCF Ratio | 11.10 |
| P/OCF Ratio | 8.01 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 0.49, with an EV/FCF ratio of 0.56.
| EV / Earnings | 0.37 |
| EV / Sales | 0.09 |
| EV / EBITDA | 0.49 |
| EV / EBIT | 0.78 |
| EV / FCF | 0.56 |
Financial Position
The company has a current ratio of 13.72, with a Debt / Equity ratio of 0.00.
| Current Ratio | 13.72 |
| Quick Ratio | 12.94 |
| Debt / Equity | 0.00 |
| Debt / EBITDA | 0.06 |
| Debt / FCF | 0.07 |
| Interest Coverage | 150.87 |
Financial Efficiency
Return on equity (ROE) is 10.31% and return on invested capital (ROIC) is 15.58%.
| Return on Equity (ROE) | 10.31% |
| Return on Assets (ROA) | 2.90% |
| Return on Invested Capital (ROIC) | 15.58% |
| Return on Capital Employed (ROCE) | 4.71% |
| Weighted Average Cost of Capital (WACC) | 6.21% |
| Revenue Per Employee | 501.47M |
| Profits Per Employee | 124.67M |
| Employee Count | 101 |
| Asset Turnover | 0.39 |
| Inventory Turnover | 3.30 |
Taxes
| Income Tax | -22.46M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +5.24% in the last 52 weeks. The beta is 0.36, so Cell Biotech's price volatility has been lower than the market average.
| Beta (5Y) | 0.36 |
| 52-Week Price Change | +5.24% |
| 50-Day Moving Average | 13,528.80 |
| 200-Day Moving Average | 13,046.10 |
| Relative Strength Index (RSI) | 46.89 |
| Average Volume (20 Days) | 40,067 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Cell Biotech had revenue of KRW 50.65 billion and earned 12.59 billion in profits. Earnings per share was 1,839.56.
| Revenue | 50.65B |
| Gross Profit | 36.48B |
| Operating Income | 5.99B |
| Pretax Income | 12.57B |
| Net Income | 12.59B |
| EBITDA | 9.65B |
| EBIT | 5.99B |
| Earnings Per Share (EPS) | 1,839.56 |
Balance Sheet
The company has 88.96 billion in cash and 577.11 million in debt, giving a net cash position of 88.38 billion or 12,913.79 per share.
| Cash & Cash Equivalents | 88.96B |
| Total Debt | 577.11M |
| Net Cash | 88.38B |
| Net Cash Per Share | 12,913.79 |
| Equity (Book Value) | 127.11B |
| Book Value Per Share | 18,573.12 |
| Working Capital | 93.72B |
Cash Flow
In the last 12 months, operating cash flow was 11.62 billion and capital expenditures -3.24 billion, giving a free cash flow of 8.39 billion.
| Operating Cash Flow | 11.62B |
| Capital Expenditures | -3.24B |
| Free Cash Flow | 8.39B |
| FCF Per Share | 1,225.36 |
Margins
Gross margin is 72.03%, with operating and profit margins of 11.82% and 24.86%.
| Gross Margin | 72.03% |
| Operating Margin | 11.82% |
| Pretax Margin | 24.82% |
| Profit Margin | 24.86% |
| EBITDA Margin | 19.05% |
| EBIT Margin | 11.82% |
| FCF Margin | 16.56% |
Dividends & Yields
This stock pays an annual dividend of 450.00, which amounts to a dividend yield of 3.20%.
| Dividend Per Share | 450.00 |
| Dividend Yield | 3.20% |
| Dividend Growth (YoY) | 33.33% |
| Years of Dividend Growth | 1 |
| Payout Ratio | 24.46% |
| Buyback Yield | n/a |
| Shareholder Yield | 3.20% |
| Earnings Yield | 13.53% |
| FCF Yield | 9.01% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Cell Biotech has an Altman Z-Score of 10.09 and a Piotroski F-Score of 4.
| Altman Z-Score | 10.09 |
| Piotroski F-Score | 4 |